LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Heterogeneity assessment of vaccine-induced effects using point-of-care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2.

    Watanabe, Yoshiyuki / Matsuba, Ikuro / Watanabe, Karin / Kunishima, Tomoyuki / Takechi, Yukako / Takuma, Tetsuo / Araki, Yasushi / Hirotsu, Nobuo / Sakai, Hiroyuki / Oikawa, Ritsuko / Danno, Hiroki / Fukuda, Masakazu / Futagami, Seiji / Wada, Kota / Yamamoto, Hiroyuki / Itoh, Fumio / Oda, Ichiro / Hatori, Yutaka / Degawa, Hisakazu

    Journal of clinical laboratory analysis

    2022  Volume 36, Issue 7, Page(s) e24545

    Abstract: Introduction: Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic even after vaccination. We aimed to identify immunological heterogeneity over time in vaccinated healthcare ... ...

    Abstract Introduction: Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic even after vaccination. We aimed to identify immunological heterogeneity over time in vaccinated healthcare workers using neutralization antibodies and neutralizing activity tests.
    Methods: Serum samples were collected from 214 healthcare workers before vaccination (pre) and on days 22, 90, and 180 after receiving the first dose of BNT162b2 vaccine (day 0). Neutralization antibody (NAb, SARS-CoV-2 S-RBD IgM/IgG) titers and two kinds of surrogate virus neutralization tests (sVNTs) were analyzed (UMIN000043851).
    Results: The NAb (SARS-CoV-2 S-RBD IgG) titer peaked on day 90 after vaccination (30,808.0 μg/ml ± 35,211; p < 0.0001) and declined on day 180 (11,678.0 μg/ml ± 33,770.0; p < 0.0001). The neutralizing activity also peaked on day 90 and declined with larger individual differences than those of IgG titer on day 180 (88.9% ± 15.0%, 64.8% ± 23.7%, p < 0.0001). We also found that the results of POCT-sVNT (immunochromatography) were highly correlated with those of conventional sVNT (ELISA).
    Conclusions: Neutralizing activity is the gold standard for vaccine efficacy evaluation. Our results using conventional sVNT showed large individual differences in neutralizing activity reduction on day 180 (64.8% ± 23.7%), suggesting an association with the difference in vaccine efficacy. POCT-sVNT is rapid and user-friendly; it might be used for triage in homes, isolation facilities, and event venues without restrictions on the medical testing environment.
    MeSH term(s) Antibodies, Viral ; BNT162 Vaccine ; COVID-19/epidemiology ; COVID-19/prevention & control ; Humans ; Immunoglobulin G ; Neutralization Tests ; Point-of-Care Systems ; SARS-CoV-2 ; Vaccines
    Chemical Substances Antibodies, Viral ; Immunoglobulin G ; Vaccines ; BNT162 Vaccine (N38TVC63NU)
    Language English
    Publishing date 2022-06-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 645095-7
    ISSN 1098-2825 ; 0887-8013
    ISSN (online) 1098-2825
    ISSN 0887-8013
    DOI 10.1002/jcla.24545
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2471: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Time-series transcriptome analysis of peripheral blood mononuclear cells obtained from individuals who received the SARS-CoV-2 mRNA vaccine.

    Watanabe, Yoshiyuki / Yamamoto, Hiroyuki / Matsuba, Ikuro / Watanabe, Karin / Kunishima, Tomoyuki / Takechi, Yukako / Takuma, Tetsuo / Araki, Yasushi / Hirotsu, Nobuo / Sakai, Hiroyuki / Oikawa, Ritsuko / Danno, Hiroki / Fukuda, Masakazu / Sugino, Ryuichi / Futagami, Seiji / Wada, Kota / Itoh, Fumio / Tateishi, Keisuke / Oda, Ichiro /
    Hatori, Yutaka / Degawa, Hisakazu

    Journal of medical virology

    2023  Volume 95, Issue 6, Page(s) e28884

    Abstract: Messenger ribonucleic acid (mRNA) vaccination against coronavirus disease 2019 (COVID-19) is an effective prevention strategy, despite a limited understanding of the molecular mechanisms underlying the host immune system and individual heterogeneity of ... ...

    Abstract Messenger ribonucleic acid (mRNA) vaccination against coronavirus disease 2019 (COVID-19) is an effective prevention strategy, despite a limited understanding of the molecular mechanisms underlying the host immune system and individual heterogeneity of the variable effects of mRNA vaccination. We assessed the time-series changes in the comprehensive gene expression profiles of 200 vaccinated healthcare workers by performing bulk transcriptome and bioinformatics analyses, including dimensionality reduction utilizing the uniform manifold approximation and projection (UMAP) technique. For these analyses, blood samples, including peripheral blood mononuclear cells (PBMCs), were collected from 214 vaccine recipients before vaccination (T1) and on Days 22 (T2, after second dose), 90, 180 (T3, before a booster dose), and 360 (T4, after a booster dose) after receiving the first dose of BNT162b2 vaccine (UMIN000043851). UMAP successfully visualized the main cluster of gene expression at each time point in PBMC samples (T1-T4). Through differentially expressed gene (DEG) analysis, we identified genes that showed fluctuating expression levels and gradual increases in expression levels from T1 to T4, as well as genes with increased expression levels at T4 alone. We also succeeded in dividing these cases into five types based on the changes in gene expression levels. High-throughput and temporal bulk RNA-based transcriptome analysis is a useful approach for inclusive, diverse, and cost-effective large-scale clinical studies.
    MeSH term(s) Humans ; COVID-19 Vaccines ; Transcriptome ; Leukocytes, Mononuclear ; SARS-CoV-2/genetics ; BNT162 Vaccine ; COVID-19/prevention & control ; RNA, Messenger/genetics ; Gene Expression Profiling ; Vaccination ; Antibodies, Viral ; mRNA Vaccines
    Chemical Substances COVID-19 Vaccines ; BNT162 Vaccine ; RNA, Messenger ; Antibodies, Viral
    Language English
    Publishing date 2023-05-23
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.28884
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1320: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top